Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-bromo-N,N-dimethyltryptamine (5-Br-DMT) is a naturally occurring brominated indole alkaloid found in marine sponges, such as *Smenospongia aurea*. It is a structural analog of N,N-dimethyltryptamine (DMT) that acts as a partial agonist at the serotonin 5-HT2A receptor and exhibits high affinity for several other serotonin receptor subtypes, including 5-HT1A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7, as well as the serotonin transporter (SERT). Preclinical research characterizes 5-Br-DMT as a non-hallucinogenic psychoplastogen, as it promotes structural neuroplasticity (dendritogenesis) and upregulates plasticity-related immediate early genes (IEGs) without inducing the head twitch response in rodents. It has demonstrated rapid antidepressant-like effects in animal models of stress-induced depression, making it a candidate for the development of next-generation antidepressants that lack the intense psychedelic effects associated with traditional tryptamines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-bromo-N,N-dimethyltryptamine.